BioNTech SE

1 day ago · fool.com

BioNTech recently experienced a clinical trial failure, followed by a clinical success several weeks later. The company's deep pipeline could enable it to launch brand-new, lucrative products over the next few years.

2 days ago · fool.com

BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback.

3 days ago · defenseworld.net

BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Earnings and Valuation This table compares BioNTech and TScan

6 days ago · fool.com

BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer.

7 days ago · 247wallst.com

Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.

8 days ago · defenseworld.net

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 41,000 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00. Following the completion of the sale, the chief executive officer directly owned 602,209 shares

8 days ago · defenseworld.net

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 45,000 shares of the company's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00. Following the sale, the chief executive officer owned 643,209 shares of the company's

10 days ago · reuters.com

BioNTech said on Monday ​that a late-stage ‌trial showed its drug candidate gotistobart ​led to a ​clinically meaningful overall survival ⁠benefit in ​a certain form of ​lung cancer compared with standard treatment.

10 days ago · globenewswire.com

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.

22 days ago · fool.com

BioNTech has not performed well in recent years, as its COVID-19 portfolio has struggled. However, the company's mRNA platform is looking increasingly valuable.